

JC12 Rec'd PCT/PTC 1 2 OCT 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | | |
|---------------------------|----------------------------|------------|-----|
| Application No.: | Based on PCT/JP2004/005947 | Art Unit: | tba |
| Filed: | Intl. Filing 23 APRIL 2004 | Examiner: | tba |
| 1 st Inventor: | Yasuaki ITO | Allowed: | |
| For: | Novel Screening Method | Batch: | |
| Atty. Dkt. No. | 3172 US0P | Paper No.: | |

Information Disclosure Statement

MAIL STOP PCT
P.O. Box 1450
Commissioner for Patents
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, Applicants request consideration of the references listed on the attached Forms PTO/SB/08A and PTO/SB/08B. A legible copy of each listed reference is herewith being provided to the Examiner.

This Information Disclosure Statement is being submitted within 3 months of the filing date of the above-identified application, and before the mailing date of the first Office Action on the merits, thus, no certification or fee is required.

Applicants respectfully request that the listed documents be considered by the Examiner and formally be made of record in the present application and that an initialed copy of the attached forms PTO/SB/08A and PTO/SB/08B be returned in accordance with MPEP §609.


Should the Examiner believe that a conference with Applicants' attorney would advance prosecution of this application, the Examiner is respectfully requested to call Applicants' attorney.

Dated: 10/11/05

(847) 383-3372
(847) 383-3391

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
475 Half Day Road
Lincolnshire, IL 60069 USA

Respectfully submitted,



Mark Chao, Ph.D., Reg. No. 37,293
Elaine M. Ramesh, Ph.D., Reg. No. 43,032
Attorney for Applicants
Customer No. 23115

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

| | | | |
|-------|---|----|---|
| Sheet | 1 | of | 3 |
|-------|---|----|---|

Complete if Known

| | |
|------------------------|----------------------------|
| Application Number | Based on PCT/JP2004/005947 |
| Filing Date | Intl. Filing 23 APRIL 2004 |
| First Named Inventor | Yasuaki ITO |
| Art Unit | tba |
| Examiner Name | tba |
| Attorney Docket Number | 3172 USOP |

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|---|--------------------------------|---|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ *Number ⁴ *Kind Code ⁵ (if known) | | | | |
| N.B./ | A2 | JP2003-024070 A - Abstract only | 01/28/2003 | Pharma Design Inc. | | |
| ↓ | A3 | WO 02/086443 A2 | 10/31/2002 | EOS Biotechnology, Inc. | | |
| | A4 | WO 02/079492 A2 | 10/10/2002 | EOS Biotechnology, Inc. | | |
| | A5 | WO 02/061087 A2 | 08/08/2002 | Lifespan Biosciences, Inc. | | |
| | A6 | WO 02/39885 A2 | 05/23/2002 | Corixa Corporation | | |
| | A7 | WO 02/071928 A2 | 09/19/2002 | Millennium Pharmaceuticals | | |

**Examiner
Signature**

Nirmal Basi

| | |
|-----------------|--|
| Date Considered | |
|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

JC12 Rec'd PCT/PTC 12 OCT 2005

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | |
|------------------------|----------------------------|
| Application Number | Based on PCT/JP2004/005947 |
| Filing Date | Intl. Filing 23 APRIL 2004 |
| First Named Inventor | Yasuaki ITO |
| Art Unit | tba |
| Examiner Name | tba |
| Attorney Docket Number | 3172 US0P |

[illegible]

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|---|--------------------------------|---|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ *Number ⁴ *Kind Code ⁵ (if known) | | | | |
| /N.B./ | A8 | WO 01/81634 A2 | 11/01/2001 | Millennium Pharmaceuticals | | |
| /N.B./ | A9 | WO 03/012104 A1 - Abstract only | 02/13/2003 | Takeda Chemical Industries | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

10/552014

JC12 Rec'd PCT/PTC 12 OCT 2005

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|--------------------------|----------------------------|------------------------|-----------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | Based on PCT/JP2004/005947 | | |
| | | Filing Date | Intl. Filing 23 APRIL 2004 | | |
| | | First Named Inventor | Yasuaki ITO | | |
| | | Art Unit | tba | | |
| | | Examiner Name | tba | | |
| Sheet | 3 | of | 3 | Attorney Docket Number | 3172 USOP |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| /N.B./ | A10 | R.G. SMITH, et al., "Growth Hormone Releasing Substances: Types and Their Receptors", Hormone Research, (1999) pp. 1-8, Vol. 51 (Suppl. 3). | |
| /N.B.A11 | | K. K. McKEE, et al., Cloning and Characterization of Two Human g Protein-Coupled Receptor Genes (GPR38) and GPR39) Related to the Growth Hormone Secretagogue and Neurotensin Receptors", Genomics, (1997), pp. 426-434, Vol. 46 | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|--------------------|---------------|-----------------|------------|
| Examiner Signature | /Nirmal Basi/ | Date Considered | 04/28/2008 |
|--------------------|---------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.